IP Library › Granted Patent US 12,209,268
Granted Patent B2
US 12,209,268 · App. 17/334,953 · Granted Jan 28, 2025

Genetically engineered gas vesicle gene clusters, genetic circuits, vectors, prokaryotic cells, compositions, methods and systems for contrast-enhanced imaging

Inventors: Raymond W. Bourdeau (Watertown, MA); Anupama Lakshmanan (Pasadena, CA); Arash Farhadi (Pasadena, CA); Mikhail G. Shapiro (Los Angeles, CA); Audrey Lee-Gosselin (Pasadena, CA)
Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY
C12Q1/10A61K49/1896A61K49/223C07K14/195C07K14/32C12N15/70C12N15/74C12N15/75
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,209,268
App. No.
17/334,953
Granted
Jan 28, 2025
Kind
B2
Abstract

Hybrid gas vesicle gene cluster (GVGC) configured for expression in a prokaryotic host are described comprising gas vesicle assembly (GVA) genes native to a GVA prokaryotic species and capable of being expressed in a functional form in the prokaryotic host, and one or more gas vesicle structural (GVS) genes native to one or more GVS prokaryotic species, at least one of the one or more GVS prokaryotic species different from the GVA prokaryotic species, and related gas vesicle reporting (GVR) genetic circuits, genetic, vectors, engineered cells, and related compositions methods and systems to produce GVs, hybrid GVGC and/or image a target site.

Claims (32)

1. A system to screen one or more candidate hybrid gas vesicle gene clusters (GVGC), each hybrid gas vesicle gene cluster encoding a gas vesicle (GV) type, the system comprising:

a prokaryotic host;

one or more polynucleotide constructs configured to be expressed in the prokaryotic host and comprising

gas vesicle assembly (GVA) genes and gas vesicle structural (GVS) genes forming the one or more candidate hybrid GV gene clusters under control of a promoter configured to be expressed in the prokaryotic host to provide the GV type, and

an imaging device configured to apply energy to the prokaryotic host to detect formation of the GV type following expression of the one or more polynucleotide constructs in the prokaryotic host,

wherein the gas vesicle assembly (GVA) genes of the polynucleotide construct are the GVA genes native to the prokaryotic host capable of forming detectable GVs in the prokaryotic host, and the gas vesicle structural (GVS) genes are native to one or more GVS prokaryotic species, with at least one of the one or more GVS prokaryotic species different from the GVA prokaryotic host.

2. The system of claim 1 , wherein the prokaryotic host is a Gram-negative bacteria.

3. The system of claim 2 , wherein the prokaryotic host is E. coli , or Salmonella.

4. The system of claim 1 , wherein the prokaryotic host is Halobacterium.

5. The system of claim 1 , wherein the constitutive and inducible prokaryotic promoters and operators suitable for regulating expression of GVs in a prokaryotic host comprise T7, T7lac, Sp6, araBAD, trp, lac, Ptac, and pL.

6. The system of claim 1 , further comprising one or more of a transcription factor binding site, an operator, an activator binding site, a repressor binding site, an enhancer, a protein-protein binding domain, an RNA binding domain, a DNA binding domain, silencer, and an insulator.

7. The system of claim 6 , wherein the transcription factor comprises at least one of AraC, LasR, LuxR, IpgC, MxiE, Gal4, GCN4, GR, SP1, and CREB.

8. The system of claim 1 , wherein the GVA genes and GVS genes have sequences codon optimized for expression in the prokaryotic host.

9. The system of claim 1 , wherein the gas vesicle assembly (GVA) genes forming the candidate GV gene cluster comprise GVA genes from Bacillus Megaterium, Anabaena flos - aquae, Serratia sp., Bukholderia thailandensis, B. megaterium, Frankia sp, Haloferax mediaterranei, Halobacterium sp, Halorubrum vacuolatum, Microcystis aeruginosa, Methanosarcina barkeri, Streptomyces coelicolor , and/or Psychromonas ingrahamii.

10. The system of claim 1 , wherein the gas vesicle structural (GVS) genes forming the candidate GV gene cluster comprise GVS genes from Bacillus Megaterium, Anabaena flos - aquae, Serratia sp., Bukholderia thailandensis, B. megaterium, Frankia sp, Haloferax mediaterranei, Halobacterium sp, Halorubrum vacuolatum, Microcystis aeruginosa, Methanosarcina barkeri, Streptomyces coelicolor , and/or Psychromonas ingrahamii.

11. The system of claim 1 , wherein the gas vesicle assembly (GVA) genes comprise GVA genes from Bacillus Megaterium, Anabaena flos - aquae , and/or Serratia sp., and the gas vesicle structural (GVS) genes forming the candidate GV gene cluster comprise GVS genes from Bacillus Megaterium, Anabaena flos - aquae, Bukholderia thailandensis, B. megaterium, Frankia sp, Haloferax mediaterranei, Halobacterium sp, Halorubrum vacuolatum, Microcystis aeruginosa, Methanosarcina barkeri, Streptomyces coelicolor , and/or Psychromonas ingrahamii.

12. The system of claim 1 , wherein the gas vesicle assembly (GVA) genes forming the candidate GV gene cluster comprise GVA genes from Bacillus Megaterium, Anabaena flos - aquae , and/or Serratia sp., and the gas vesicle structural (GVS) genes forming the candidate GV gene cluster comprise GVA genes from Bacillus Megaterium and/or Anabaena flos - aquae.

13. The system of claim 1 , wherein the gas vesicle assembly (GVA) genes comprise B. megaterium GVA genes GvpR, GvpN, GvpF, GvpG, GvpL, GvpS, GvpK, GvpJ, GvpT and/or GvpU.

14. The system of claim 1 , wherein the gas vesicle assembly (GVA) genes comprise B. megaterium GVA genes GvpA, GvpF, GvpG, GvpJ, GvpL, GvpK, GvpS, and GvpU.

15. The system of claim 1 , wherein the polynucleotidic construct comprises one polynucleotide construct in which the GVA genes and GVS genes of a GVGC are provided in one operon, operatively connected and under regulatory control of a same promoter.

16. The system of claim 1 , wherein the polynucleotidic construct comprises a plurality of polynucleotides, in which a subset of the GVA genes and GVS genes are comprised in one operon, operatively connected and under regulatory control of a first promoter, and another subset of all of the GVA genes and GVS genes are comprised in another operon, operatively connected and under regulatory control of a second promoter.

17. The system of claim 1 , wherein the polynucleotide construct is within an expression vector selected from a plasmid DNA and a viral vector.

18. The system of claim 1 , further comprising reagents for introducing the polynucleotide construct in the prokaryotic host and detecting formation of the GV type.

19. The system of claim 1 wherein the energy applied by the imaging device is a magnetic field and the imaging device is a magnetic resonance imaging (MRI) imaging device.

20. The system of claim 1 wherein the energy applied by the imaging device is ultrasound waves and the imaging device is an ultrasound imaging device.

21. The system of claim 1 wherein the energy applied by the imaging device is an electron beam and the imaging device is a transmission electron microscope.

22. A system to screen one or more candidate hybrid gas vesicle gene clusters (GVGC), each hybrid gas vesicle gene cluster encoding a gas vesicle (GV) type, the system comprising:

a prokaryotic host:

one or more polynucleotide constructs configured to be expressed in the prokaryotic host and comprising

gas vesicle assembly (GVA) genes and gas vesicle structural (GVS) genes forming the one or more candidate hybrid GV gene clusters under control of a promoter configured to be expressed in the prokaryotic host to provide the GV type, and

an imaging device configured to apply energy to the prokaryotic host to detect formation of the GV type following expression of the one or more polynucleotide constructs in the prokaryotic host,

wherein the one or more polynucleotide constructs comprise a candidate GV gene cluster native to a prokaryotic species other than the prokaryotic host for identification and selection of GVA genes capable of being expressed in a functional form in the prokaryotic host.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2021
From: HERITAGE MEDICAL RESEARCH INSTITUTE
To: CALIFORNIA INSTITUTE OF TECHNOLOGY
Reel/Frame 056416/0601 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 31, 2021
From: BOURDEAU, RAYMOND W.; LAKSHMANAN, ANUPAMA; FARHADI, ARASH; LEE-GOSSELIN, AUDREY
To: CALIFORNIA INSTITUTE OF TECHNOLOGY
Reel/Frame 056395/0635 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 31, 2021
From: SHAPIRO, MIKHAIL G.
To: CALIFORNIA INSTITUTE OF TECHNOLOGY; HERITAGE MEDICAL RESEARCH INSTITUTE
Reel/Frame 056395/0645 →
Continuity (4)
Continuation 15663635 · Jul 28, 2017
Provisional Application 62413206 · Oct 26, 2016
Provisional Application 62367750 · Jul 28, 2016
Related Publication 20210301298A1 · Sep 30, 2021
References Cited (92)
US 5558092A · Unger et al. · 1996 [cited by applicant]
US 11118210B2 · Bourdeau et al. · 2021 [cited by applicant]
US 11446523B2 · Bar-Zion et al. · 2022 [cited by applicant]
US 11504438B2 · Lakshmanan et al. · 2022 [cited by applicant]
US 11761008B2 · Farhadi et al. · 2023 [cited by applicant]
US 11786218B2 · Sawyer et al. · 2023 [cited by applicant]
US 12109440B2 · Bar-Zion et al. · 2024 [cited by applicant]
US 20020115717A1 · Gervais et al. · 2002 [cited by applicant]
US 20030147812A1 · Ueberle · 2003 [cited by applicant]
US 20040204922A1 · Beadle et al. · 2004 [cited by applicant]
US 20040265393A1 · Unger et al. · 2004 [cited by applicant]
US 20060025683A1 · Hoffmann · 2006 [cited by applicant]
US 20060058618A1 · Nishiura · 2006 [cited by applicant]
US 20100069757A1 · Yoshikawa et al. · 2010 [cited by applicant]
US 20100239170A1 · Asnis · 2010 [cited by applicant]
US 20120020878A1 · Qi · 2012 [cited by applicant]
US 20230139561A1 · Bari-Zion et al. · 2023 [cited by applicant]
US 20230277695A1 · Lakshmanan et al. · 2023 [cited by applicant]
US 20230357780A1 · Farhadi et al. · 2023 [cited by applicant]
EP 3908656A1 · 2021 [cited by applicant]
WO 2018043716A1 · 2018 [cited by applicant]
WO 2020146379A1 · 2020 [cited by applicant]
EPO Communication pursuant to Rules 161(2) and 162 EPC for EP Application No. 20739042 filed on Jul. 14, 2021 on behalf of California Institute of Technology Mail Date: Aug. 18, 2021. 3 pages. [cited by applicant]
Extended European Search Report for EP Application No. 20739042.8 filed on Jan. 7, 2020 on behalf of California Institute of Technology Mail Date: Sep. 5, 2022. 10 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 16/736,581, filed Jan. 7, 2020 on behalf of California Institute of Technology Mail Date: Dec. 13, 2021. 50 pages. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2020/012557 filed on Jan. 7, 2020, on behalf of California Institute of Technology. Mail Date: Jul. 22, 2021. 8 Pages. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2020/012572 filed on Jan. 7, 2020, on behalf of California Institute of Technology. Mail Date: Jul. 22, 2021. 8 Pages. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2020/048572 filed on Aug. 28, 2020 on behalf of California Institute of Technology Mail Date: Mar. 1, 2022. 7 pages. [cited by applicant]
International Preliminary Report on Patentability for International PCT Application No. PCT/US2020/025608 filed on Mar. 29, 2020 filed on behalf of California Institute of Technology. Mail Date: Sep. 28, 2021. 7 Pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/736,581, filed Jan. 7, 2020, on behalf of California Institute of Technology. Mail Date: Aug. 6, 2021. 62 Pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/736,581, filed Jan. 7, 2020 on behalf of California Institute of Technology Mail Date: May 31, 2022. 51 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/833,637, filed Mar. 29, 2020 on behalf of California Institute of Technology Mail Date: Jan. 25, 2022. 26 pages. [cited by applicant]
Non-Final Office Action issued for U.S. Appl. No. 16/736,683, filed Jan. 7, 2020, on behalf of California Institute of Technology. Mail Date: Apr. 8, 2022. 36 Pages. [cited by applicant]
Notice of Allowability for U.S. Appl. No. 16/656,417, filed Oct. 17, 2019, on behalf of California Institute of Technology. Mail Date: Sep. 29, 2022. 4 Pages. [cited by applicant]
Notice of Allowability for U.S. Appl. No. 16/833,637, filed Mar. 29, 2020, on behalf of California Institute of Technology. Mail Date: Aug. 17, 2022. 9 Pages. [cited by applicant]
Notice of Allowability for U.S. Appl. No. 16/833,637, filed Mar. 29, 2020 on behalf of California Institute of Technology Mail Date: Jun. 13, 2022. 6 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/656,417, filed Oct. 17, 2019, on behalf of California Institute of Technology. Mail Date: Dec. 8, 2021. 7 Pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/656,417, filed Oct. 17, 2019 on behalf of California Institute of Technology Mail Date: Jun. 27, 2022. 9 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/656,417, filed Oct. 17, 2019, on behalf of California Institute of Technology. Mail Date: Mar. 31, 2022. 19 Pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/656,417, filed Oct. 17, 2019, on behalf of California Institute of Technology. Mail Date: Sep. 3, 2021. 9 Pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/736,581, filed Jan. 7, 2020, on behalf of California Institute of Technology. Mail Date: Sep. 29, 2022. 34 Pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/833,637, filed Mar. 29, 2020 on behalf of California Institute of Technology Mail Date: May 16, 2022. 12 pages. [cited by applicant]
Restriction Requirement for U.S. Appl. No. 16/736,683, filed Jan. 7, 2020 on behalf of California Institute of Technology Mail Date: Sep. 14, 2021. 8 pages. [cited by applicant]
Restriction Requirement issued for U.S. Appl. No. 17/006,591, filed Aug. 28, 2020, on behalf of California Institute of Technology. Mail Date: Sep. 8, 2022. 12 Pages. [cited by applicant]
Aguino, Carmen F. et al; “Single component biohybrid light-emitting diodes using a white-emitting fused protein.” ACS Omega (2018) 3, p. 15829-15836. [cited by applicant]
Andreev, Y., et al., “Cyanogen Bromide Cleavage of Proteins in Salt and Buffer Solutions.” [cited by applicant]
Cesaratto, Francesca et al; “Engineered tobacco etch virus (TEV) protease active in the secretory pathway of mammalian cells.” J. Biotech. (2015) 212, p. 159-166. [cited by applicant]
Ciechanover, A., et al., “Ubiquitin-Mediated Proteolysis: Biological Regulation via Destruction.” [cited by applicant]
Corrected Notice of Allowability for U.S. Appl. No. 16/656,417, filed Oct. 17, 2019, on behalf of California Institute of Technology. Mail Date: Oct. 20, 2022. 4 Pages. [cited by applicant]
Corrected Notice of Allowability issued for U.S. Appl. No. 16/736,683, filed Jan. 7, 2020, on behalf of California Institute of Technology. Mail Date: Aug. 3, 2023. 7 Pages. [cited by applicant]
Corrected Notice of Allowability issued for U.S. Appl. No. 16/736,683, filed Jan. 7, 2020, on behalf of California Institute of Technology. Mail Date: Feb. 23, 2023. 7 Pages. [cited by applicant]
Dutka, P. et al., Structure of Anabaena flos-aquae gas vesicles revealed by cryo-ET. Structure, 31, 518-528. 18 pages. May 4, 2023. Website: doi.org/10.1016/j.str.2023.03.011. [cited by applicant]
“Enzyme” definition and meaning from Merriam Webster dictionary website. (Last updated Nov. 4, 2023). [cited by applicant]
“Enzyme” Definition, Mechanisms, and Nomenclature. Last updated on Dec. 10, 2023. 13 pages. Downloaded from website: www.britannica.com/science/enzyme. [cited by applicant]
“Enzyme” from NIH: National Human Genome Research Institute. Downloaded through The Wayback Machine with a date of Jul. 9, 2019. 1 page. [cited by applicant]
Final Office Action issued for U.S. Appl. No. 17/006,591, filed Aug. 28, 2020, on behalf of California Institute of Technology. (Mail Date: Nov. 9, 2023). 21 Pages. [cited by applicant]
Herrmann, Joerg et al; “Ubiquitin and ubiquitin-like proteins in protein regulation.” Circulation Research (May 2007) 100, p. 1276-1291. [cited by applicant]
Jiang et al., “Tumor imaging by means of proteolytic activation of cell penetrating peptides,” PNAS vol. 101 No. 51, Dec. 21, 2004. 17862-17872 (6 pages). [cited by applicant]
Lux, Jacques et al; “Thrombin-activatable microbubbles as potential ultrasound contrast agents for the detection of acute thrombosis.” ACS Appl. Mater. Interfaces (Nov. 2017) 9(43), p. 37587-37596. 22 pages. [cited by applicant]
Non-Final Office Action issued for U.S. Appl. No. 17/006,591, filed Aug. 28, 2020, on behalf of California Institute of Technology. Mail Date: Apr. 14, 2023. 39 Pages. [cited by applicant]
Notice of Allowability for U.S. Appl. No. 16/736,581, filed Jan. 7, 2020 on behalf of California Institute of Technology Mail Date: Jul. 19, 2023 8 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/736,581, filed Jan. 7, 2020 on behalf of California Institute of Technology. Mail Date: Jan. 23, 2023. 14 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/736,581, filed Jan. 7, 2020 on behalf of California Institute of Technology Mail Date: Jun. 16, 2023. 11 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/816,373, filed Jul. 29, 2022 on behalf of California Institute of Technology, mailed on Jun. 8, 2023. 13 pages. [cited by applicant]
Notice of Allowance issued for U.S. Appl. No. 16/736,683, filed Jan. 7, 2020, on behalf of California Institute of Technology. Mail Date: Jan. 6, 2023. 11 Pages. [cited by applicant]
Notice of Allowance issued for U.S. Appl. No. 16/736,683, filed Jan. 7, 2020, on behalf of California Institute of Technology. Mail Date: May 31, 2023. 11 Pages. [cited by applicant]
Notice of Allowance issued for U.S. Appl. No. 17/816,373, filed Jul. 29, 2022 on behalf of California Institute of Technology. Mail Date: Dec. 4, 2023. 10 pages. [cited by applicant]
Perona, J. et al. “Structural basis of substrate specificity in the serine proteases”, Protein Science, (1995), 4, 337-360. Cambridge University Press. [cited by applicant]
Supplemental Notice of Allowability for U.S. Appl. No. 16/736,581, filed Jan. 7, 2020 on behalf of California Institute of Technology Mail Date: Feb. 13, 2023 3 pages. [cited by applicant]
The PubChem database entry for “Cyanogen Bromide”, (downloaded Nov. 2, 2023). 89 pages. [cited by applicant]
“Thrombin” from Wikipedia, the online encyclopedia, downloaded from The Wayback Machine for Mar. 23, 2018. 24 pages. [cited by applicant]
To, Tsz-Leung et al; “Rationally designed fluorogenic protease reporter visualizes spatiotemporal dynamics of apoptosis in vivo.” PNAS (Mar. 2015) 112(11), p. 3338-3343. [cited by applicant]
Waldner, B.J. et al. “Electrostatic recognition in substrate binding to serine proteases”, Journal of Molecular Recognition 31, e2727.10 (2018), 12 pages. Website: doi.org/10/1002/jmr.2727. [cited by applicant]
Anderson, Caleb F. et al, “Protease sensitive nanomaterials for cancer therapeutics and imaging.” Ind. Eng. Chem. Res. (2017) 56, p. 5761-5777. 17 pages. [cited by applicant]
Carson, M., et al., “His-tag impact on structure,” Acta Cryst. (2007). D63, 295-301. 7 pages. [cited by applicant]
Certification Statement and List—37 CFR 1.98(d)(1) filed in U.S. Appl. No. 17/334,953, filed May 31, 2021 on behalf of California Institute of Technology. 1 page. [cited by applicant]
Dos Santos, Nancy, et al, “Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding.” Biochim. Biophys. Acta (2007) 1768, p. 1367-1377… [cited by applicant]
Dutka, P. et al., Supplemental Information—Structure of Anabaena flos-aquae gas vesicles revealed by cryo-ET. Structure, 31, 20 pages. May 4, 2023. [cited by applicant]
“Enzyme” Definition, Mechanisms, and Nomenclature, from Encyclopaedia Britannica (Britannica.com). 3 pages. Downloaded through the Wayback Machine for Jun. 29, 2019. [cited by applicant]
“Enzyme” Definition, Mechanisms, and Nomenclature. Last updated on Mar. 4, 2024. 13 pages. Downloaded from website: www.britannica.com/science/enzyme. Retrieved Mar. 29, 2024. [cited by applicant]
Final Office Action issued for U.S. Appl. No. 17/006,591, filed Aug. 28, 2020, on behalf of California Institute of Technology. Mail Date: Jul. 18, 2024. 24 Pages. [cited by applicant]
Green, Anthony et al, “In vitro testing of a protease sensitive contrast agent for optoacoustic imaging.” J. Biomed. Optics (Mar./Apr. 2010) 15(2) 021315. 8 pages. [cited by applicant]
Law, Benedict et al, “Protease sensitive fluorescent nanofibers.” Bioconj. Chem. (2007) 18, p. 1701-1704. [cited by applicant]
National Human Genome Research Institute, “Enzyme-less DNA base discrimination using solid-state nanopores with high-frequency integrated detection electronics” Project Description (Project End date: Jun. 30, 2019). Ret… [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 18/046,881, filed Oct. 14, 2022 on behalf of California Institute of Technology. Mailed on Jul. 15, 2024. 14 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 18/317,915, filed May 15, 2023 on behalf of California Institute of Technology. Mailed on Jun. 10, 2024. 17 pages. [cited by applicant]
Notice of Allowability issued for U.S. Appl. No. 17/816,373, filed Jul. 29, 2022 on behalf of California Institute of Technology. Mail Date: Jun. 25, 2024. 5 pages. [cited by applicant]
Notice of Allowance issued for U.S. Appl. No. 17/816,373, filed Jul. 29, 2022 on behalf of California Institute of Technology. Mail Date: Jun. 4, 2024. 11 pages. [cited by applicant]
Sciencelearn web page on enzymes in laundry detergent: website web.archive.org/web/20170521005639/https://www.sciencelearn.org.nz/resources/1947-enzymes-in-washing-powders. According to USPTO examiner in U.S. Appl. No. … [cited by applicant]
Tang, Haichao et al, “The analysis of key factors related to ADSs structural design.” Front. Pharmacol. (Apr. 2019) 10:373. 11 pages. [cited by applicant]
Notice of Allowability issued for U.S. Appl. No. 17/816,373, filed Jul. 29, 2022 on behalf of California Institute of Technology. Mail Date: Sep. 13, 2024. 5 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 18/317,915, filed May 15, 2023 on behalf of California Institute of Technology. Mailed on Oct. 22, 2024. 12 pages. [cited by applicant]